Clinical characteristics of type 2 diabetes patients with discordance between HbA1c and fasting plasma glucose in the real world: an analysis of the ORBIT study.

Hua Shu,Juming Lu,Puhong Zhang,Dongshan Zhu,Xian Li,Jiachao Ji,Fang Zhao,Linong Ji
DOI: https://doi.org/10.1002/dmrr.2977
2018-01-01
Abstract:Background: We aimed to determine the clinical characteristics of type 2 diabetes patients on basal insulin therapy with inadequate glucose control due to discordance between glycated haemoglobin (HbA(1c)) and fasting plasma glucose (FPG) in the real world. Methods: This was a retrospective analysis of data from the ORBIT study in China. Clinical characteristics of patients with discordance between HbA(1c) and FPG at baseline and at the end of 6 months of follow-up were analysed using multinomial logistic regression in 4 study groups divided by HbA(1c) and FPG. Results: Overall, of 6721 patients initiated on basal insulin, 853 achieved HbA(1c) < 7% but FPG >= 7mmol/L (group 2), while 997 had FPG < 7 mmol/L but HbA(1c)7% (group 3) at the end of follow-up. Patients in group 3 had a longer duration of type 2 diabetes compared with those in group 2 (7.225.30 vs 6.00 +/- 4.80y, P < .05). Patients on glargine (32.90%) or detemir (36.88%) treatment accounted for a higher proportion of patients with both HbA(1c) and FPG controlled than those on neutral protamine Hagedorn therapy (23.45%; P < .05). Per the multinomial logistic analysis, higher frequency of self-monitoring of blood glucose (SMBG) and use of glargine or detemir therapy were significantly inversely associated with risk of discordance between HbA(1c) and FPG, while dose of insulin was a risk factor for discordance at the end of follow-up (all P < .05). Conclusions: Patients treated with insulin analogues (glargine or detemir), instead of neutral protamine Hagedorn, and with more frequent SMBG are more likely to exhibit concordance between HbA(1c) and FPG.
What problem does this paper attempt to address?